ArticleVirology journal2011
Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice.
Article in Virology journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Swine Group A rotavirus vaccines: current status, adjuvant strategies, challenges, and future perspectives.Frontiers in veterinary science · 2026Review
- A pilot study on a heterologous prime-boost approach for inducing an immune response against double-layered human rotavirus particles.BMC research notes · 2025Article
- Review
- Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.Archives of virology · 2022Review
- Emerging Concepts and Technologies in Vaccine Development.Frontiers in immunology · 2020Review
- Virus-like particle vaccines: immunology and formulation for clinical translation.Expert review of vaccines · 2018Review
- Immune response of mature cows subjected to annual booster vaccination against neonatal calf diarrhoea with two different commercial vaccines: A non-inferiority study.Livestock science · 2017Article
- Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana.Virology journal · 2015Article
- Chimaeric virus-like particles derived from consensus genome sequences of human rotavirus strains co-circulating in Africa.PloS one · 2014Article
- Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.Human vaccines & immunotherapeutics · 2014Article
- Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.Human vaccines & immunotherapeutics · 2013Article
- Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles.Journal of translational medicine · 2013Article
- Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.PloS one · 2013Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRotavirus (RV) is the main cause of severe gastroenteritis in children. An effective vaccination regime against RV can substantially reduce morbidity and mortality. Previous studies have demonstrated the efficacy of virus-like particles formed by RV VP2 and VP6 (VLP2/6), as well as that of recombinant adenovirus expressing RV VP6 (rAd), in eliciting protective immunities against RV. However, the efficacy of such prime-boost strategy, which incorporates VLP and rAd in inducing protective immunities against RV, has not been addressed. We assessed the immune effects of different regimens in mice, including rAd prime-VLP2/6 boost (rAd+VLP), VLP2/6 prime-rAd boost (VLP+rAd), rAd alone, and VLP alone.
resultsMice immunized with the VLP+rAd regimen elicit stronger humoral, mucosal, and cellular immune responses than those immunized with other regimens. RV challenging experiments showed that the highest reduction (92.9%) in viral shedding was achieved in the VLP+rAd group when compared with rAd+VLP (25%), VLP alone (75%), or rAd alone (40%) treatment groups. The reduction in RV shedding in mice correlated with fecal IgG (r = 0.95773, P = 0.04227) and IgA (r = 0.96137, P = 0.038663).
conclusionsA VLP2/6 prime-rAd boost regimen is effective in conferring immunoprotection against RV challenge in mice. This finding may lay the groundwork for an alternative strategy in novel RV vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.